253 related articles for article (PubMed ID: 27071922)
1. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Bendell JC; Javle M; Bekaii-Saab TS; Finn RS; Wainberg ZA; Laheru DA; Weekes CD; Tan BR; Khan GN; Zalupski MM; Infante JR; Jones S; Papadopoulos KP; Tolcher AW; Chavira RE; Christy-Bittel JL; Barrett E; Patnaik A
Br J Cancer; 2017 Feb; 116(5):575-583. PubMed ID: 28152546
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
[TBL] [Abstract][Full Text] [Related]
6. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
8. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA
Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
10. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
Finn RS; Ahn DH; Javle MM; Tan BR; Weekes CD; Bendell JC; Patnaik A; Khan GN; Laheru D; Chavira R; Christy-Bittel J; Barrett E; Sawyer MB; Bekaii-Saab TS
Invest New Drugs; 2018 Dec; 36(6):1037-1043. PubMed ID: 29785570
[TBL] [Abstract][Full Text] [Related]
11. Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Froesch P; Mark M; Rothschild SI; Li Q; Godar G; Rusterholz C; Oppliger Leibundgut E; Schmid S; Colombo I; Metaxas Y; König D; Sessa C; Gautschi O; Früh M;
Lung Cancer; 2021 Jun; 156():91-99. PubMed ID: 33933896
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
13. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; Eckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM
Clin Cancer Res; 2010 Mar; 16(5):1613-23. PubMed ID: 20179232
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
de Weger VA; de Jonge M; Langenberg MHG; Schellens JHM; Lolkema M; Varga A; Demers B; Thomas K; Hsu K; Tuffal G; Goodstal S; Macé S; Deutsch E
Br J Cancer; 2019 Feb; 120(3):286-293. PubMed ID: 30585255
[TBL] [Abstract][Full Text] [Related]
15. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
Dickson MA; Gordon MS; Edelman G; Bendell JC; Kudchadkar RR; LoRusso PM; Johnston SH; Clary DO; Schwartz GK
Invest New Drugs; 2015 Apr; 33(2):349-56. PubMed ID: 25476894
[TBL] [Abstract][Full Text] [Related]
17. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
[TBL] [Abstract][Full Text] [Related]
18. Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.
Lowery MA; Bradley M; Chou JF; Capanu M; Gerst S; Harding JJ; Dika IE; Berger M; Zehir A; Ptashkin R; Wong P; Rasalan-Ho T; Yu KH; Cercek A; Morgono E; Salehi E; Valentino E; Hollywood E; O'Reilly EM; Abou-Alfa GK
Clin Cancer Res; 2019 Feb; 25(3):937-945. PubMed ID: 30563938
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
Wagner AJ; Messersmith WA; Shaik MN; Li S; Zheng X; McLachlan KR; Cesari R; Courtney R; Levin WJ; El-Khoueiry AB
Clin Cancer Res; 2015 Mar; 21(5):1044-51. PubMed ID: 25388167
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
Bekaii-Saab T; Phelps MA; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA
J Clin Oncol; 2011 Jun; 29(17):2357-63. PubMed ID: 21519026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]